Strata Critical Medical (SRTA) stock
Members see every stock ranked and every check behind each score, live.
Why SRTA scores 9
AverageTrending up, 4 of 13 possible checks firingWhat the Quality Score means
- +4Momentum traits 4 firing right now, of 13 possible, one point each
- +3Growth sales up 67% on the year, gross margin up 1.9 points
- Long-term trend adds
- Profit adds
- Cash flow subtracts
What's next
Expected to report Mon Nov 9, before the open
After its last 4 reports it closed +6.8% on average, higher 4 of 4 times.
What would move SRTA's score: 5 things, for members
Here is what members see.
Every stock gets a card like this one, and a page with its price in real time, every line of its score, the chart, and its filings.
SRTA has 4 of a possible 13 checks firing
14 checks. Two are opposites (heavy volume and quiet volume), so at most 13 are on at once. One per group is shown here.
How SRTA ranks in Services-Health Services
SRTA is #3 of 7 by Quality Score. The top three are shown with their scores, and the rest by name.
PNTG7/1317
LFST4/1313
SRTA4/139
INNVOpen for its score
WGSOpen for its score
When does SRTA report, and what happens after?
Expected to report Mon Nov 9, before the open (in 42 days). Not yet confirmed by the company.
| Reported | When | Gap | Reaction | 5 sessions |
|---|---|---|---|---|
| Aug 4, 2026Before open | Before open | -2.7% | +0.4% | +7.0% |
| May 6, 2026Before open | Before open | +13.9% | +10.6% | +13.5% |
| Mar 3, 2026Before open | Before open | +9.1% | +6.9% | +1.8% |
| Nov 10, 2025Before open | Before open | +7.7% | +9.5% | +8.1% |
Who is trading SRTA
Insiders
5 insiders sold $450K across 5 filings in the last 6 months. No open-market buys on record. The newest:
About Strata Critical Medical
Strata Critical Medical Inc is a time-critical logistics and medical services provider to the U.S. healthcare industry. The group operates one of the nation's air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated 'One Call' solution for donor organ recovery. It includes two segments: Logistics segments which hold, Air Logistics, Ground Logistics and Organ Placement. The second segment is Clinical Segment which includes: Organ Recovery, Normothermic Regional Perfusion (NRP), and Preservation, and Other Clinical Segment which has Cardiac Care, and Other.
Every line of the score, on every stock.
- Real-time prices, no delay
- Every line of SRTA's score, with the points and the reason
- All 14 checks on SRTA and on all 2,951 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on SRTA
Straight answers.
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Members, trial included, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week traits rest on real history. Options flow is not part of the product.
What does it cost?
One plan with everything in it: $29 a month, $69 for three months, or $249 a year. You pick the billing period when the trial ends, and payments go through Stripe, so Breakaway never sees your card.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.